Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Preferred Stock Liabilities (2020)

Caribou Biosciences (CRBU) has disclosed Preferred Stock Liabilities for 1 consecutive years, with $41.3 million as the latest value for Q4 2020.

  • Quarterly Preferred Stock Liabilities changed N/A to $41.3 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $41.3 million through Dec 2020, changed N/A year-over-year, with the annual reading at $41.3 million for FY2020, N/A changed from the prior year.
  • Preferred Stock Liabilities for Q4 2020 was $41.3 million at Caribou Biosciences.
  • The five-year high for Preferred Stock Liabilities was $41.3 million in Q4 2020, with the low at $41.3 million in Q4 2020.